Mission Statement, Vision, & Core Values of Intellia Therapeutics, Inc. (NTLA)

In the dynamic world of gene editing, Intellia Therapeutics, Inc. (NTLA) stands out as a pioneering force, but do you know what truly drives this company? With a mission focused on transforming lives through potentially curative genome editing treatments, Intellia is pushing the boundaries of medicine. In 2024, the company reported revenue of $57.87 million, marking an increase from $36.27 million in 2023, but what are the core values that guide their innovative work, and how do these values translate into their strategic vision?

Intellia Therapeutics, Inc. (NTLA) An Overview of

Founded in 2014, Intellia Therapeutics is a biotechnology company focused on developing curative therapeutics using CRISPR/Cas9 technology. Their approach involves both in vivo and ex vivo gene editing therapies. In vivo therapies involve directly delivering the gene editing machinery into the patient’s body to modify cells within their natural environment, while ex vivo therapies involve modifying cells outside the body, which are then transplanted back into the patient. Intellia's leading programs target genetic diseases with significant unmet medical needs.

As of April 2025, Intellia Therapeutics has several ongoing clinical trials. While specific recent sales figures for their therapies are not yet available (as of April 2025), due to the developmental stage of their products, the company's financial performance is primarily reflected in its strategic collaborations, R&D investments, and overall financial health. For detailed insights into Intellia's financial standing, you can explore: Breaking Down Intellia Therapeutics, Inc. (NTLA) Financial Health: Key Insights for Investors

In Intellia Therapeutics' most recent financial reports, the company highlighted several key achievements and financial figures. While they have no approved products yet, their financial stability is reflected in their strategic partnerships and substantial investments in research and development. For example, in the fiscal year 2024, Intellia reported a strong cash position, ending the year with approximately $789.7 million in cash, cash equivalents and marketable securities, which supports their ongoing clinical trials and research programs. Collaboration revenues play a crucial role, with partnerships contributing significantly to their financial resources. These collaborations not only provide funding but also validate their technology and therapeutic approaches.

Intellia Therapeutics stands out as one of the leading companies in the gene editing industry due to its pioneering work with CRISPR/Cas9 technology and its comprehensive approach to developing both in vivo and ex vivo therapies. The company's strategic collaborations, strong financial position, and promising clinical trial results underscore its potential to revolutionize the treatment of genetic diseases. To delve deeper into understanding what makes Intellia a key player in the biotech industry, continue reading below.

Intellia Therapeutics, Inc. (NTLA) Mission Statement

The mission of Intellia Therapeutics, Inc. (NTLA) is to transform the lives of people with severe diseases by developing potentially curative genome editing treatments.

The company is dedicated to developing curative gene-editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. Intellia aims to revolutionize medicine through the development of innovative gene editing therapies, harnessing the power of CRISPR technology to treat severe genetic disorders and provide hope and healing to patients worldwide.

The mission's core components focus on:

• Developing Curative Treatments: Focusing on creating therapies that address the root cause of genetic diseases rather than just managing symptoms.
• Transforming Lives: Aiming to make a significant positive impact on the well-being of patients and their families.
• Severe Diseases: Targeting conditions that have a significant impact on quality of life and for which there are limited treatment options.

Intellia's commitment to its mission is evident in its strategic priorities and clinical programs. The company is focused on advancing its late-stage programs, such as NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) for ATTR amyloidosis.

The company has initiated dosing in the global Phase 3 HAELO study for NTLA-2002 in HAE and expects to complete enrollment in the second half of 2025, with a Biologics License Application (BLA) submission planned for the second half of 2026. The Phase 3 MAGNITUDE trial for nex-z in ATTR amyloidosis is also progressing ahead of schedule, with over 550 patients expected to be enrolled by the end of the year.

These efforts reflect Intellia's dedication to translating its mission into tangible results for patients. The company's financial results for 2024 demonstrate its commitment to investing in research and development to achieve its mission. For example, for the fourth quarter of 2024, Intellia's collaboration revenue was $12.9 million, and its research and development expenses were $116.9 million.

Intellia's mission also influences its corporate culture, which values teamwork, exploration, innovation, and dedication. The company fosters a culture that encourages employees to push boundaries and challenge conventional thinking to develop innovative solutions.

The company's values are:

• One
• Explore
• Disrupt
• Deliver

These values guide Intellia's employees in their daily work and reinforce the company's commitment to its mission of transforming the lives of patients with severe diseases.

For more insights into Intellia Therapeutics, explore: Exploring Intellia Therapeutics, Inc. (NTLA) Investor Profile: Who’s Buying and Why?

Intellia Therapeutics, Inc. (NTLA) Vision Statement of

Intellia Therapeutics, Inc. is a biotechnology company focused on developing potentially curative therapeutics using CRISPR technology. Understanding Intellia's vision, mission, and core values provides insight into its strategic direction and operational priorities. As of April 2025, here's an overview based on the latest available information.

Mission Statement

Intellia Therapeutics' mission is centered on leveraging CRISPR/Cas9 technology to develop curative therapies for genetic diseases. While a specific, formally declared mission statement might not be explicitly publicized, their actions and communications consistently highlight this core objective. The company focuses on:

• Developing in vivo and ex vivo CRISPR-based therapies.
• Addressing diseases with significant unmet medical needs.
• Advancing a pipeline of therapeutic programs with the potential to transform treatment paradigms.

This mission is evident in their strategic partnerships, clinical trial programs, and research and development efforts. For example, Intellia's collaboration with Regeneron to develop in vivo therapies underscores their commitment to addressing diseases directly within the body. In the fiscal year 2024, Intellia reported a research and development expense of $481.7 million, reflecting its dedication to advancing its therapeutic programs.

Vision Statement

Intellia's vision is to revolutionize the treatment of genetic diseases through the application of CRISPR/Cas9 technology. The elements of this vision include:

• Innovation in CRISPR Technology: Continuously improving the precision and efficiency of CRISPR-based gene editing.
• Broad Therapeutic Application: Expanding the application of CRISPR technology to a wide range of diseases.
• Leadership in Gene Editing: Establishing themselves as a leader in the field of gene editing, driving the development of next-generation therapies.

This vision is reflected in Intellia's ongoing research and development activities, including advancements in delivery methods and target identification. As of 2024, Intellia had a cash balance of $1.1 billion, providing substantial resources to support its ambitious research and development programs. Their strategic focus involves:

• Pioneering the development of potentially curative CRISPR-based therapies.
• Advancing programs through clinical trials to demonstrate safety and efficacy.
• Collaborating with leading organizations to expand their technological and therapeutic reach.

Core Values

Intellia Therapeutics' core values drive its culture and operational practices. While not always explicitly stated, these values are evident in their approach to innovation, collaboration, and patient care. Key values include:

• Innovation: A commitment to pushing the boundaries of scientific knowledge and technological capabilities.
• Collaboration: Fostering partnerships with researchers, clinicians, and other stakeholders to accelerate therapeutic development.
• Integrity: Adhering to the highest ethical standards in research, development, and business practices.
• Patient Focus: Prioritizing the needs of patients and developing therapies that can significantly improve their lives.

These values are exemplified in their dedication to rigorous scientific inquiry, transparency in their communications, and a patient-centric approach to therapeutic development. For example, Intellia's commitment to innovation is demonstrated by its investment in novel delivery systems for CRISPR payloads, aimed at improving the specificity and effectiveness of gene editing. In 2024, Intellia continued to emphasize these values, allocating significant resources to support both internal research programs and external collaborations.

In summary, Intellia Therapeutics, Inc. is driven by a clear mission to develop curative therapies using CRISPR/Cas9 technology, guided by a vision of revolutionizing the treatment of genetic diseases, and underpinned by core values of innovation, collaboration, integrity, and patient focus. These elements collectively shape Intellia's strategic direction and operational priorities, positioning the company as a key player in the rapidly evolving field of gene editing.

To gain more insights into the investors and stakeholders involved with Intellia Therapeutics, explore this profile: Exploring Intellia Therapeutics, Inc. (NTLA) Investor Profile: Who’s Buying and Why?

Intellia Therapeutics, Inc. (NTLA) Core Values

While specific, publicly available details regarding Intellia Therapeutics' (NTLA) core values are limited as of April 2025, we can analyze their mission, vision, and actions to infer key principles that guide their operations. These inferred values emphasize innovation, patient focus, and scientific rigor.

Innovation

Innovation is likely a core value at Intellia. Their mission is focused on developing potentially curative therapeutics using CRISPR/Cas9 technology. This inherently requires a commitment to pushing the boundaries of science and technology.

Examples of how Intellia demonstrates its commitment to innovation include:

• Pioneering CRISPR Technology: Intellia is focused on utilizing CRISPR/Cas9 technology, which represents a cutting-edge approach to gene editing.
• Robust Pipeline: Intellia has a diverse pipeline of therapeutic programs targeting various diseases. For example, NTLA-2001 is being developed as a potentially curative treatment for Transthyretin (ATTR) Amyloidosis. Initial data presented in 2024 showed promising results.
• Strategic Collaborations: Intellia collaborates with other companies and academic institutions to advance its research and development efforts.

Patient Focus

Given their focus on developing potentially curative medicines, a strong patient focus is likely a core value. This means prioritizing the needs and well-being of patients in all aspects of their work.

Examples of how Intellia demonstrates its commitment to patient focus include:

• Targeting Serious Diseases: Intellia focuses on developing therapies for diseases with significant unmet medical needs.
• Clinical Trial Design: Intellia designs its clinical trials with patient safety and convenience in mind.
• Patient Advocacy: Intellia likely engages with patient advocacy groups to understand the needs of patients and families affected by the diseases they are targeting.

Scientific Rigor

As a biotechnology company, Intellia places a high value on scientific rigor. This includes conducting thorough research, adhering to high ethical standards, and transparently communicating their findings.

Examples of how Intellia demonstrates its commitment to scientific rigor include:

• Data Transparency: Intellia presents data from its preclinical and clinical studies at scientific conferences and in peer-reviewed publications.
• Experienced Team: Intellia employs a team of experienced scientists and clinicians with expertise in CRISPR technology and drug development.
• Ethical Standards: Intellia adheres to high ethical standards in its research and development activities.

To gain more insights into Intellia Therapeutics, Inc. (NTLA), consider exploring their investor profile: Exploring Intellia Therapeutics, Inc. (NTLA) Investor Profile: Who’s Buying and Why?